+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05427(LTB Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

Lymphotoxin-beta (LTβ), a member of the tumor necrosis factor (TNF) superfamily, plays a critical role in lymphoid organ development, immune cell trafficking, and inflammatory responses. It primarily forms a heterotrimer with lymphotoxin-alpha (LTα), which binds to the LTβ receptor (LTβR) to activate signaling pathways such as NF-κB and MAPK. This interaction is essential for maintaining the structure of secondary lymphoid tissues and regulating adaptive immunity. Dysregulated LTβ signaling has been implicated in autoimmune diseases, chronic inflammation, and cancer progression.

LTβ antibodies are engineered to either block or modulate LTβ-LTβR interactions. Blocking antibodies inhibit LTβR signaling, potentially suppressing pathological immune responses in conditions like rheumatoid arthritis or inflammatory bowel disease. Conversely, agonist antibodies may enhance receptor activation, which could promote lymphoid neogenesis or anti-tumor immunity. Research also explores their utility in targeting LTβ-expressing cells in certain lymphomas. Recent studies focus on optimizing antibody specificity and pharmacokinetics, with some candidates progressing to preclinical or early clinical trials. These antibodies represent a promising therapeutic avenue for diseases linked to lymphoid tissue dysfunction or aberrant immune activation, though their clinical efficacy and safety profiles require further validation.